Article in Archiv der Pharmazie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Felipe Cardoso Prado MartinsMedicinal and Biological Chemistry Group, São Carlos Institute of Chemistry, University of São Paulo, São Carlos, São Paulo, Brazil.ORCID https://orcid.org/0000-0002-5030-9431
Johannes LangMedicinal Chemistry, Institute of Pharmacy and Molecular Biotechnology IPMB, Heidelberg University, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-8215-6302
Fernanda Dos Reis RochoMedicinal and Biological Chemistry Group, São Carlos Institute of Chemistry, University of São Paulo, São Carlos, São Paulo, Brazil.
Xianxian WangMedicinal Chemistry, Institute of Pharmacy and Molecular Biotechnology IPMB, Heidelberg University, Heidelberg, Germany.
Vinícius BonattoMedicinal and Biological Chemistry Group, São Carlos Institute of Chemistry, University of São Paulo, São Carlos, São Paulo, Brazil.
Jerônimo LameiraMedicinal and Biological Chemistry Group, São Carlos Institute of Chemistry, University of São Paulo, São Carlos, São Paulo, Brazil.
Christian KleinMedicinal Chemistry, Institute of Pharmacy and Molecular Biotechnology IPMB, Heidelberg University, Heidelberg, Germany.
Carlos Alberto MontanariMedicinal and Biological Chemistry Group, São Carlos Institute of Chemistry, University of São Paulo, São Carlos, São Paulo, Brazil.
Funding
This project was supported by the Volkswagen Foundation under grant number 9A836 ("Preclinical development of antiviral protease inhibitors targeting flavi- and coronaviruses"). This project was also funded by the Sao Paulo Research Foundation (FAPESP) under scholarships #2021/09433-3, #2020/07222-2, and #2022/01393-5 and by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil (CAPES)-Finance Code 001.
6 · The paper itself
Abstract
The COVID-19 pandemic underscored the urgent need for effective antiviral agents, particularly against coronaviruses, which pose a continuing threat of future outbreaks. Targeting the main protease (M
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Exploring Nirmatrelvir Derivatives Through P2 Substituent Modifications and Warhead Innovations Targeting the Main Protease of SARS-CoV-2. · full record | OpenQuestion